{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:50:56Z","timestamp":1788814256162,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s12149-022-01798-6","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T15:24:40Z","timestamp":1666884280000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL)"],"prefix":"10.1007","volume":"37","author":[{"given":"Junki","family":"Takenaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7930-0975","authenticated-orcid":false,"given":"Shiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashige","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohsuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"1798_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol. 2022;33:90\u2013114.","journal-title":"Endocr Pathol"},{"key":"1798_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jso.24063","volume":"112","author":"YM Choi","year":"2015","unstructured":"Choi YM, Sung T-Y, Kim WG, Lee JJ, Ryu J-S, Kim TY, et al. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience. J Surg Oncol. 2015;112:815\u201321.","journal-title":"J Surg Oncol"},{"key":"1798_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jso.24030","volume":"112","author":"T Ezzat Abdel-Aziz","year":"2015","unstructured":"Ezzat Abdel-Aziz T, Prete F, Conway G, Gaze M, Bomanji J, Bouloux P, et al. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes. J Surg Oncol. 2015;112:486\u201391.","journal-title":"J Surg Oncol"},{"key":"1798_CR4","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1476\u201390.","journal-title":"Ann Oncol"},{"key":"1798_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","volume":"80","author":"LT van Hulsteijn","year":"2014","unstructured":"van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EPM. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;80:487\u2013501.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1798_CR6","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","volume":"25","author":"HJLM Timmers","year":"2007","unstructured":"Timmers HJLM, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262\u20139.","journal-title":"J Clin Oncol"},{"key":"1798_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/jnci\/djs188","volume":"104","author":"HJLM Timmers","year":"2012","unstructured":"Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104:700\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1798_CR8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00259-011-1872-3","volume":"38","author":"A Nakazawa","year":"2011","unstructured":"Nakazawa A, Higuchi T, Oriuchi N, Arisaka Y, Endo K. Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma. Eur J Nucl Med Mol Imaging. 2011;38:1869\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1798_CR9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s12149-021-01664-x","volume":"35","author":"Y Uchiyama","year":"2021","unstructured":"Uchiyama Y, Hirata K, Watanabe S, Okamoto S, Shiga T, Okada K, et al. Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2021;35:1223\u201331.","journal-title":"Ann Nucl Med"},{"key":"1798_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.oraloncology.2012.09.005","volume":"49","author":"YG Abd El-Hafez","year":"2013","unstructured":"Abd El-Hafez YG, Moustafa HM, Khalil HF, Liao C-T, Yen T-C. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:261\u20138.","journal-title":"Oral Oncol."},{"key":"1798_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12032-014-0446-1","volume":"32","author":"M Xie","year":"2015","unstructured":"Xie M, Wu K, Liu Y, Jiang Q, Xie Y. Predictive value of F-18 FDG PET\/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2015;32:446.","journal-title":"Med Oncol"},{"key":"1798_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s13139-012-0165-5","volume":"46","author":"SW Yoo","year":"2012","unstructured":"Yoo SW, Kim J, Chong A, Kwon S-Y, Min J-J, Song H-C, et al. Metabolic tumor volume measured by F-18 FDG PET\/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer. Nucl Med Mol Imaging. 2012;46:286\u201393.","journal-title":"Nucl Med Mol Imaging"},{"key":"1798_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105682","volume":"9","author":"K Hirata","year":"2014","unstructured":"Hirata K, Kobayashi K, Wong K-P, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE. 2014;9: e105682.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"1798_CR14","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150.","journal-title":"J Nucl Med"},{"key":"1798_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.684668","volume":"12","author":"L Zheng","year":"2021","unstructured":"Zheng L, Gu Y, Silang J, Wang J, Luo F, Zhang B, et al. Prognostic nomograms for predicting overall survival and cancer-specific survival of patients with malignant pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2021;12: 684668.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1798_CR16","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","volume":"48","author":"G Eisenhofer","year":"2012","unstructured":"Eisenhofer G, Lenders JWM, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48:1739\u201349.","journal-title":"Eur J Cancer"},{"key":"1798_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/cen.13357","volume":"87","author":"X Zhong","year":"2017","unstructured":"Zhong X, Ye L, Su TW, Xie J, Zhou W, Jiang Y, et al. Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2017;87:127\u201335.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1798_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1530\/eje.0.1470085","volume":"147","author":"E van der Harst","year":"2002","unstructured":"van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SWJ, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol. 2002;147:85\u201394.","journal-title":"Eur J Endocrinol"},{"key":"1798_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1210\/jc.2010-1946","volume":"96","author":"M Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96:717\u201325.","journal-title":"J Clin Endocrinol Metab"},{"key":"1798_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/jso.23297","volume":"107","author":"P Goffredo","year":"2013","unstructured":"Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107:659\u201364.","journal-title":"J Surg Oncol"},{"key":"1798_CR21","first-page":"1107","volume":"12","author":"S Nagura","year":"1999","unstructured":"Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T, Omata K. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol. 1999;12:1107\u201311.","journal-title":"Mod Pathol"},{"key":"1798_CR22","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1210\/jc.2006-0423","volume":"91","author":"FM Brouwers","year":"2006","unstructured":"Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91:4505\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1798_CR23","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jc.2012-4231","volume":"98","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez M, Palmer JL, Hofmann M-C, de la Cruz M, Moon BS, Waguespack SG, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013;98:1492\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1798_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s12149-021-01699-0","volume":"36","author":"A Inaki","year":"2022","unstructured":"Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, et al. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. Ann Nucl Med. 2022;36:267\u201378.","journal-title":"Ann Nucl Med"},{"key":"1798_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2967\/jnumed.120.250803","volume":"62","author":"K Yoshinaga","year":"2021","unstructured":"Yoshinaga K, Abe T, Okamoto S, Uchiyama Y, Manabe O, Ito YM, et al. Effects of repeated 131I-meta-iodobenzylguanidine radiotherapy on tumor size and tumor metabolic activity in patients with metastatic neuroendocrine tumors. J Nucl Med. 2021;62:685\u201394.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-022-01798-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:06:03Z","timestamp":1672841163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-022-01798-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1798"],"URL":"https:\/\/doi.org\/10.1007\/s12149-022-01798-6","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no potential conflicts of interest related to the content of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}